Methods and Compositions for Treating Cancer
AssigneeOmeros Corporation
InventorsMichael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Marc A. Gavin, Alexander Gragerov, Thomas L. Little, Rene Onrust
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
Claims73
A method of treating cancer, the method comprising administering to a patient a therapeutically effective amount of a GPR174 inhibitor that inhibits a GPR174 G-alpha-s signaling thereby stimulating an immune response in the patient.
A method of increasing the level of Th1 cytokines in human peripheral blood mononuclear cells (PBMCs), the method comprising contacting the human PBMCs with a small-molecule inhibitor of GPR174 signaling and at least one of an adenosine-A2A (A2A) receptor antagonist, an adenosine-A2B (A2B) receptor antagonist, or a combination thereof.
A pharmaceutical composition comprising a combination of an inhibitor of GPR174 signaling and at least one of an adenosine-A2A (A2A) receptor antagonist an adenosine-A2B (A2B) receptor antagonist, a CD73 inhibitor and/or a CD38 inhibitor, or a CD39 inhibitor and a pharmaceutically acceptable excipient.
A pharmaceutical composition comprising a therapeutically effective amount of a combination of a GPR174 inhibitory compound and a Treg attenuating agent in a pharmaceutically acceptable carrier.
A method of enhancing an anti-tumor immune response in a subject that is currently undergoing, or has undergone, treatment with at least one of an A2aR antagonist, an A2bR antagonist, a CD38 inhibitor, a CD39 inhibitor, a CD73 inhibitor and/or a Treg attenuating agent, comprising administering an effective amount of a GPR174 inhibitor to stimulate an enhanced anti-tumor response in the subject.
A method of stimulating and/or amplifying an immune response in a mammalian subject suffering from, or at risk of developing cancer or cancer metastasis, comprising:
- (a) determining the presence of cancer cell-derived exosome(s) expressing phosphatidylserine (PS) in a sample obtained from said mammalian subject;
- and
- (b) administering a therapeutically effective amount of a GPR174 inhibitor to said subject.
Dependencies are inferred from the claim text.